P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and knee osteoarthritis, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
The analysis, conducted between December 2025 and January 2026, was part of an ongoing cross-sectional study examining GLP-1 RA use among people with eating disorders in the US
Rather than relying on willpower alone, these medications work with the bodys natural signaling systems to regulate appetite, improve insulin response, and support sustainable metabolic change
However, given the clinical trial results in people without type 1 diabetes [260], these agents may have a role for those with type 1 diabetes who have concomitant obesity
When administered in pulsatile fashion, it stimulates the pituitary gland to release LH and FSH, the same hormones that tell your testes to produce testosterone and sperm
